Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1
Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1